Annals of Diagnostic Pathology, Journal Year: 2025, Volume and Issue: 75, P. 152438 - 152438
Published: Jan. 13, 2025
Language: Английский
The Journal of Immunology, Journal Year: 2025, Volume and Issue: unknown
Published: March 21, 2025
Abstract Therapeutic B cell depletion with monoclonal antibodies targeting CD20 forced a rethink about the pathogenic role of cells and plasma in autoimmune diseases; however, it was tempered by frequent clinical relapses or nonresponse to CD20-directed therapy. Here, we re-evaluate strategies autoimmunity prompted 4 recent advances. The first is analysis clonal accumulations CD20− CD19+ making autoantibodies patients anti-CD20 refractory disease. second remarkable remissions induced anti-CD19 chimeric antigen receptor T cases autoimmunity. third evidence that comprise majority humans, are not terminally differentiated, long-lived, if self-reactive have potent capacity capture autoantigens via their surface immunoglobulin present major histocompatibility complex class II–bound peptides. fourth autoantigen-binding as key antigen-presenting “T cell–mediated” disorders, type 1 diabetes celiac Viewing human memory from this alternative perspective offers an explanation for why deep CD19 compartmental may be effective at achieving complete durable autoantibody-positive diseases group, irrespective whether autoantibody pathogenic.
Language: Английский
Citations
1
Frontiers in Pharmacology, Journal Year: 2024, Volume and Issue: 15
Published: April 24, 2024
Epigenetic modifications, characterized by changes in gene expression without altering the DNA sequence, play a crucial role development and progression of cancer significantly influencing activity cellular function. This insight has led to novel class therapeutic agents, known as epigenetic drugs. These drugs, including histone deacetylase inhibitors, acetyltransferase methyltransferase aim modulate curb growth uniquely landscape cells. Ongoing research clinical trials are rigorously evaluating efficacy these particularly their ability improve outcomes when used combination with other treatments. Such therapies may more effectively target potentially overcome challenge drug resistance, significant hurdle therapy. Additionally, importance nutrition, inflammation control, circadian rhythm regulation modulating responses been increasingly recognized, highlighting critical modifiers thereby effectiveness pharmacological interventions patient outcomes. drugs represent paradigm shift treatment, offering targeted that promise precise approach treating wide spectrum tumors, fewer side effects compared traditional chemotherapy. progress marks step towards personalized interventions, leveraging unique profiles individual tumors optimize treatment strategies.
Language: Английский
Citations
8
Gastroenterology, Journal Year: 2024, Volume and Issue: 167(1), P. 34 - 50
Published: Jan. 28, 2024
Language: Английский
Citations
7
Nutrients, Journal Year: 2024, Volume and Issue: 16(7), P. 976 - 976
Published: March 27, 2024
Immunoreactive gluten peptides that are not digested by peptidases produced humans can trigger celiac disease, allergy and non-celiac hypersensitivity. The aim of this study was to evaluate the ability selected probiotic strains hydrolyze immunoreactive gliadin identify peptidase-encoding genes in genomes most efficient strains. Residual immunoreactivity measured after one- or two-step hydrolysis using commercial enzymes bacterial peptidase preparations G12 R5 immunoenzymatic assays. Peptidase from Lacticaseibacillus casei LC130, paracasei LPC100 Streptococcus thermophilus ST250 significantly reduced peptides, including 33-mer, effect markedly higher when a mixture these used. In silico genome analyses L. LC130 revealed presence encoding with potential bonds proline-rich peptides. This suggests S. ST250, especially used as mixture, have could be administered patients on restricted gluten-free diet help treat gluten-related diseases.
Language: Английский
Citations
7
Clinical Immunology, Journal Year: 2024, Volume and Issue: 260, P. 109923 - 109923
Published: Feb. 4, 2024
Celiac Disease (CD) is a T-cell mediated disorder caused by immune response to gluten, although the mechanisms underlying CD progression are still elusive. We analyzed cell composition, plasma cytokines, and gliadin-specific responses in patients with positive serology normal intestinal mucosa (potential-CD) or villous atrophy (acute-CD), after gluten-free diet (GFD). found: an inflammatory signature presence of circulating IFN-γ
Language: Английский
Citations
6
Gastroenterology, Journal Year: 2024, Volume and Issue: 167(1), P. 183 - 193
Published: Feb. 13, 2024
Language: Английский
Citations
5
Gut, Journal Year: 2024, Volume and Issue: 73(5), P. 844 - 853
Published: Feb. 20, 2024
Serum antibodies to the autoantigen transglutaminase 2 (TG2) are increasingly harnessed diagnose coeliac disease. Diagnostic guidelines for children give recommendation a no-biopsy-based diagnosis through detection of high amounts IgA anti-TG2 in serum with confirmation positivity separate blood sample by characteristic autoantibody-staining tissue. While measurement also is important diagnostic workup adults, adult still mandate examination gut biopsies. This requirement might well change future, as necessity confirming autoantibody tissue staining. The key role serology disease paradoxical. Coeliac was considered, and can be food intolerance disorder where autoantibodies at face value out place. immunological mechanisms underlying formation response gluten exposure have been dissected. review presents current insights demonstrating that intimately integrated maladapted immune gluten.
Language: Английский
Citations
5
Gastroenterology, Journal Year: 2024, Volume and Issue: 167(2), P. 250 - 263
Published: March 28, 2024
The treatment of celiac disease (CeD) with gluten-free diet (GFD) normalizes gut inflammation and disease-specific antibodies. CeD patients have HLA-restricted, gluten-specific T cells persisting in the blood even after decades GFD, which are reactivated driving upon gluten exposure. Our aim was to examine transition activated into a pool memory concurrent normalization clinically relevant biomarkers during first year treatment.
Language: Английский
Citations
5
Digestive Diseases and Sciences, Journal Year: 2024, Volume and Issue: 69(7), P. 2548 - 2557
Published: April 29, 2024
Non-responsive coeliac disease (NRCD), where symptoms and enteropathy persist despite a prolonged gluten-free diet (GFD), is common. Refractory (RCD), characterised by malabsorption extensive enteropathy, rare but serious. In both, treatment options are limited. Topical budesonide may help an open capsule format promoting proximal small intestinal delivery be advantageous.
Language: Английский
Citations
5
JGH Open, Journal Year: 2024, Volume and Issue: 8(7)
Published: July 1, 2024
Abstract The traditional gut‐centric view of coeliac disease is evolving as immune and genetic insights underscore the central importance a systemic, T cell response to gluten in pathogenesis. As field increasingly recognize limitations small intestinal histology diagnostic standard, data supporting accuracy an (serologic) diagnosis ‐ well demonstrated children are growing for adults. Novel biomarkers such interleukin‐2 that identify gluten‐specific demonstrate high sensitivity specificity offer potential approach avoids need challenge. Asymptomatic manifestations outside gut pose considerable challenges using case‐finding strategy enthusiasm population screening growing. gluten‐free diet remains highly restrictive treatment there paucity controlled inform safe intake threshold. Ongoing symptoms enteropathy common require systematic evaluation. Slowly‐responsive prevalent older patient diagnosed with disease, super‐sensitivity emerging concept may explain many cases nonresponsive disease. While great interest developing novel therapies no drug has yet been registered. Efficacy studies generally assessing drugs patients treated who undergo challenge or disease; however, substantial questions remain around specific endpoints relevant patients, clinicians regulatory agencies optimal trial design. tools providing informative readouts clinical trials now shaping their
Language: Английский
Citations
5